drug supply chain (December 2025 update) Falsified OZEMPIC (semaglutide) identified in the WHO Regions of Americas and Europe (WHO Medical Product Alert, June 2024) FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S
That partnership ended in June 2025, with Novo Nordisk citing concerns over Hims compounded versions of semaglutide and marketing practices
Accessibility: If you are vision-impaired or have some other impairment covered by the Americans with Disabilities Act or a similar law, and you wish to discuss potential accommodations related to using this website, please contact our Accessibility Manager at (512) 572-6634.
Available at: 77 GibsonW
[DOI] [PubMed] [PMC] Kaplowitz N, Win S, Than TA, Liu ZX, Dara L
Prioritizing protein content, fat, calorie, and sugar reduction while boosting the nutritional value of products will be essential to support GLP-1 usage for weight reduction